Bettina C Henzi, Simone Schmidt, Sara Nagy, Daniela Rubino-Nacht, Sabine Schaedelin, Niveditha Putananickal, Georgia Stimpson, Helge Amthor, Anne-Marie Childs, Nicolas Deconinck, Imelda de Groot, Iain Horrocks, Saskia Houwen-van Opstal, Vincent Laugel, Mercedes Lopez Lobato, Marcos Madruga Garrido, Andrés Nascimento Osorio, Ulrike Schara-Schmidt, Stefan Spinty, Arpad von Moers, Fiona Lawrence, Patricia Hafner, Olivier M Dorchies, Dirk Fischer
BACKGROUND: Drug repurposing could provide novel treatment options for Duchenne muscular dystrophy. Because tamoxifen-an oestrogen receptor regulator-reduced signs of muscular pathology in a Duchenne muscular dystrophy mouse model, we aimed to assess the safety and efficacy of tamoxifen in humans as an adjunct to corticosteroid therapy over a period of 48 weeks. METHODS: We did a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 12 study centres in seven European countries...
October 2023: Lancet Neurology